Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Operating profit is projected to rise 10% to 16%, revised from 16% to 24%. Novo Nordisk said the outlook was revised due to lower expectations for Wegovy in the U.S. and selected international markets ...